Eli Lilly and Company (NYSE: LLY) has been examined closely by Jim Cramer. He emphasized the significance of the company’s GLP-1 medication, stating:
“I recommend considering Eli Lilly for its exceptional GLP-1 drug aimed at diabetes and weight management. These are its most prominent applications. However, by the end of this year, I believe its potential could expand to areas from hypertension, often dubbed the silent killer, to dementia, and potentially issues like alcoholism. The stock has seen a slowdown largely due to the drug’s cumbersome delivery system.”
Image Source: Pixabay/Public Domain
Eli Lilly and Company (NYSE: LLY) focuses on the development and marketing of pharmaceuticals across various fields including diabetes, obesity, cancer treatments, immunology, neuroscience, and gastrointestinal disorders.
While we recognize the investment potential of LLY, we argue that certain AI stocks present better upside opportunities with reduced downside risk. For those in search of an undervalued AI stock poised to gain from Trump-era tariffs and the trend of onshoring, check out our complimentary report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article was originally published at Insider Monkey.
